Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Cardiovascular Diabetology|April 10, 2013
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory studyChristine Berndt-Zipfel, Georg Michelson, Markus Dworak, et al.
Journal of Diabetes Science and Technology|August 28, 2012
Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skillsAndreas Pfützner, Christina Schipper, Marcus Niemeyer, et al.
Journal of the American College of Cardiology|January 24, 2007
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyMarkolf Hanefeld, Nikolaus Marx, Andreas Pfützner, et al.
Diabetes Technology & Therapeutics|October 24, 2009
Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen deviceThomas Forst, Cloth Hohberg, Thomas Schöndorf, et al.
Diabetes & Metabolic Syndrome|September 1, 2016
Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patientsThorsten Siegmund, Martin Pfohl, Thomas Forst, et al.
Clinical Laboratory|November 20, 2010
Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders?Marco Klemm, Moritz Eidens, Marion Lorenz, et al.
Diabetes Technology & Therapeutics|July 10, 2010
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim studyAndreas Pfützner, Michael Derwahl, Stephan Jacob, et al.
Swiss Medical Weekly|November 8, 2002
Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meterAndreas Pfützner, Norbert Hermanns, Stefan Schröder, et al.
Atherosclerosis|April 1, 2008
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT studyWolfgang Leonhardt, Andreas Pfützner, Jürgen Müller, et al.
Journal of Diabetes Science and Technology|February 27, 2013
Hematocrit interference of blood glucose meters for patient self-measurementSanja Ramljak, John Paul Lock, Christina Schipper, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Cardiovascular Diabetology|April 10, 2013
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory studyChristine Berndt-Zipfel, Georg Michelson, Markus Dworak, et al.
Journal of Diabetes Science and Technology|August 28, 2012
Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skillsAndreas Pfützner, Christina Schipper, Marcus Niemeyer, et al.
Journal of the American College of Cardiology|January 24, 2007
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyMarkolf Hanefeld, Nikolaus Marx, Andreas Pfützner, et al.
Diabetes Technology & Therapeutics|October 24, 2009
Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen deviceThomas Forst, Cloth Hohberg, Thomas Schöndorf, et al.
Diabetes & Metabolic Syndrome|September 1, 2016
Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patientsThorsten Siegmund, Martin Pfohl, Thomas Forst, et al.
Clinical Laboratory|November 20, 2010
Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders?Marco Klemm, Moritz Eidens, Marion Lorenz, et al.
Diabetes Technology & Therapeutics|July 10, 2010
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim studyAndreas Pfützner, Michael Derwahl, Stephan Jacob, et al.
Swiss Medical Weekly|November 8, 2002
Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meterAndreas Pfützner, Norbert Hermanns, Stefan Schröder, et al.
Atherosclerosis|April 1, 2008
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT studyWolfgang Leonhardt, Andreas Pfützner, Jürgen Müller, et al.
Journal of Diabetes Science and Technology|February 27, 2013
Hematocrit interference of blood glucose meters for patient self-measurementSanja Ramljak, John Paul Lock, Christina Schipper, et al.
Pageof 15